Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Review, H2 2016', provides in depth analysis on Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted pipeline therapeutics. The report provides comprehensive information on the Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - The report reviews Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics and enlists all their major and minor projects - The report assesses Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) Overview 7 Therapeutics Development 8 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Stage of Development 8 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Therapy Area 9 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Indication 10 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Companies 14 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Products under Development by Universities/Institutes 16 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Companies Involved in Therapeutics Development 24 AstraZeneca Plc 24 Cantex Pharmaceuticals Inc 25 Chiesi Farmaceutici SpA 26 Kyorin Pharmaceutical Co Ltd 27 Polyphor Ltd 28 Proteo Inc 29 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Drug Profiles 30 ANV-201 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 AZD-9668 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 brevenal - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 dociparstat sodium - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 KRP-109 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 POL-6014 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Polysaccharides to Inhibit P-Selectin and HLE for Age-Related Macular Degeneration - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecule 1 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecule 2 to Inhibit Neutrophil Elastase for Immunology, Oncology and Respiratory Disorders - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 tiprelestat - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Dormant Projects 46 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Discontinued Products 50 Neutrophil Elastase (Bone Marrow Serine Protease or Elastase 2 or Medullasin or PMN Elastase or Human Leukocyte Elastase or ELANE or EC 3.4.21.37) - Featured News & Press Releases 51 Jun 06, 2016: Proteo receives US$ 1 million grant for a new Elafin drug formulation 51 Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia 51 Sep 01, 2015: Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I 51 Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01 52 May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting 53 Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 54 Nov 21, 2014: Final Analysis of the Phase II Clinical Study on Elafin in coronary artery bypass surgery completed 54 May 20, 2014: $ 4.8 Million Funding for Proteo's Advanced Orphan Drug Development 55 Nov 08, 2013: Proteo, Inc. / Proteo Biotech AG: Patient Recruitment and Treatment in Elafin CABG Phase II Clinical Trial Completed 55 Mar 20, 2013: Proteo's Elafin Obtains FDA Orphan Drug Designation For Prevention Of Inflammatory Complications Of Transthoracic Esophagectomy 56 Jan 10, 2013: Proteo's Elafin Receives FDA Orphan Drug Designation For Treatment Of Pulmonary Arterial Hypertension 56 Dec 11, 2012: Proteo Announces Patient Recruitment For EMPIRE Study Of Elafin Surpassed Expectations 57 Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants 58 Jun 22, 2012: Proteo Provides Update On Phase II Study Of Elafin In Coronary Bypass Surgery 58 Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 59 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Assessment by Monotherapy/Combination Products, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 23 Pipeline by AstraZeneca Plc, H2 2016 24 Pipeline by Cantex Pharmaceuticals Inc, H2 2016 25 Pipeline by Chiesi Farmaceutici SpA, H2 2016 26 Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 27 Pipeline by Polyphor Ltd, H2 2016 28 Pipeline by Proteo Inc, H2 2016 29 Dormant Projects, H2 2016 46 Dormant Projects (Contd..1), H2 2016 47 Dormant Projects (Contd..2), H2 2016 48 Dormant Projects (Contd..3), H2 2016 49 Discontinued Products, H2 2016 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.